X
27Jul

Bio-Rad Geenius HIV 1/2 Implementation

0 Comments | | Return |

CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.

Read all about it on the Communication page by clicking this link: Communications

 

 

Related

CTS Implements HLA Class I and II Testing on the Gemini

CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...

Read More >

National Blood Donor Month

Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...

Read More >

FDA Guidance for Industry for Babesia

On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...

Read More >

Upcoming HCV Testing Algorithm Change

FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...

Read More >

Reminder- Check flights and cargo hours for the 4th of July Day Holiday

As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...

Read More >

Updated Sample Acceptability Document

CTS was recently notified that one of the tubes listed in the Sample Acceptability document...

Read More >

Subscribe here to receive CTS updates!

Name